Q-omics provides the consensus-scored DCAF4L2 profile across patient tissues and cancer cell-line models. DCAF4L2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCAF4L2 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, DCAF4L2 RNA expression shows 9,844 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where DCAF4L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF4L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF4L2 survival associations across molecular data types. DCAF4L2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF4L2 RNA expression–survival associations across cancer types. High DCAF4L2 expression shows unfavorable associations in KIRC, ACC, LUSC, READ and LUAD, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for DCAF4L2 RNA expression.
This table summarizes DCAF4L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for DCAF4L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF4L2 shows higher tumor expression in LIHC and PRAD. The LIHC box plot shows higher DCAF4L2 RNA expression in tumor versus normal tissue (log2 FC = +1.876, t-test p < 0.001).
This table shows molecular features associated with DCAF4L2 in patient tissues and cancer cell lines. In patient samples, DCAF4L2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF4L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
